Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBIG + GM-CSF + HBV vaccine
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
This combination immunotherapy regimen is being evaluated by Beijing 302 Hospital for the treatment of chronic hepatitis B (CHB). The regimen consists of Hepatitis B Immune Globulin (HBIG), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and a Hepatitis B vaccine, administered in conjunction with standard nucleoside analogue therapy. The therapeutic strategy aims to overcome immune exhaustion and achieve HBsAg seroconversion in patients who have already achieved HBeAg seroconversion. HBIG is used to neutralize circulating HBsAg, while GM-CSF acts as an adjuvant to enhance dendritic cell function and antigen presentation. The HBV vaccine is intended to stimulate a de novo HBV-specific immune response. This multi-component approach is designed to restore host immunity and improve the clinical outcome of chronic HBV infection.
- Other names
- HBIG+GM-CSF+HBV vaccineHBIG + GM-CSF + Hepatitis B vaccineHepatitis B immune globin + granulocyte-macrophage colony-stimulating factor + HBV vaccine
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HBIG + GM-CSF + HBV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBIG + GM-CSF + HBV vaccine.